Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10579149,apparent oral clearance,Disulfiram treatment decreased 6-hydroxychlorzoxazone formation clearance by nearly 95% but effected only a modest decrease in vesnarinone apparent oral clearance (5.7 +/- 1.0 vs. 5.0 +/- 0.5 ml/min; p = 0.022).,Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579149/),[ml] / [min],5.7,14005,DB00822,Disulfiram
,10579149,apparent oral clearance,Disulfiram treatment decreased 6-hydroxychlorzoxazone formation clearance by nearly 95% but effected only a modest decrease in vesnarinone apparent oral clearance (5.7 +/- 1.0 vs. 5.0 +/- 0.5 ml/min; p = 0.022).,Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579149/),[ml] / [min],5.0,14006,DB00822,Disulfiram
,10579149,Cmax,"The Cmax of OPC-18692 was increased approximately 7-fold, and the area under the plasma concentration-time curve was increased 18-fold (2.9 +/- 0.9 vs. 53.7 +/- 33.2 micrograms.h/ml; p = 0.006).",Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579149/),[h·μg] / [ml],2.9,14007,DB00822,Disulfiram
,10579149,area under the plasma concentration-time curve,"The Cmax of OPC-18692 was increased approximately 7-fold, and the area under the plasma concentration-time curve was increased 18-fold (2.9 +/- 0.9 vs. 53.7 +/- 33.2 micrograms.h/ml; p = 0.006).",Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579149/),[h·μg] / [ml],2.9,14008,DB00822,Disulfiram
,10579149,area under the plasma concentration-time curve,"The Cmax of OPC-18692 was increased approximately 7-fold, and the area under the plasma concentration-time curve was increased 18-fold (2.9 +/- 0.9 vs. 53.7 +/- 33.2 micrograms.h/ml; p = 0.006).",Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579149/),[h·μg] / [ml],53.7,14009,DB00822,Disulfiram
,8595092,minimum absorption,"Based on the excretion of radioactivity in urine, the minimum absorption was about 73%.","Fate and distribution of [14C]S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine, an antimutagenic mixed disulfide from disulfiram, in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595092/),%,73,27870,DB00822,Disulfiram
,8595092,Cmax,"Mean Cmax value for N,N-diethyldithiocarbamate (DDTC) after oral dose of AC-DDTC (20 mg/kg) was 3.8 +/- 0.2 nmol/ml at 15 min and the mean residence time was 47.1 +/- 2.8 min.","Fate and distribution of [14C]S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine, an antimutagenic mixed disulfide from disulfiram, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595092/),[nM] / [ml],3.8,27871,DB00822,Disulfiram
,8595092,mean residence time,"Mean Cmax value for N,N-diethyldithiocarbamate (DDTC) after oral dose of AC-DDTC (20 mg/kg) was 3.8 +/- 0.2 nmol/ml at 15 min and the mean residence time was 47.1 +/- 2.8 min.","Fate and distribution of [14C]S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine, an antimutagenic mixed disulfide from disulfiram, in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595092/),min,47.1,27872,DB00822,Disulfiram
,8513656,elimination clearance,"Disulfiram pretreatment markedly decreased chlorzoxazone elimination clearance to 15% of control values (from 3.28 +/- 1.40 to 0.49 +/- 0.07 ml/kg/min, p < 0.005), prolonged the elimination half-life (from 0.92 +/- 0.32 to 5.1 +/- 0.9 hours, p < 0.001), and caused a twofold increase in peak plasma chlorzoxazone concentrations (20.6 +/- 9.9 versus 38.7 +/- 10.3 micrograms/ml, p < 0.001).",Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513656/),[ml] / [kg·min],3.28,40734,DB00822,Disulfiram
,8513656,elimination clearance,"Disulfiram pretreatment markedly decreased chlorzoxazone elimination clearance to 15% of control values (from 3.28 +/- 1.40 to 0.49 +/- 0.07 ml/kg/min, p < 0.005), prolonged the elimination half-life (from 0.92 +/- 0.32 to 5.1 +/- 0.9 hours, p < 0.001), and caused a twofold increase in peak plasma chlorzoxazone concentrations (20.6 +/- 9.9 versus 38.7 +/- 10.3 micrograms/ml, p < 0.001).",Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513656/),[ml] / [kg·min],0.49,40735,DB00822,Disulfiram
,8513656,elimination half-life,"Disulfiram pretreatment markedly decreased chlorzoxazone elimination clearance to 15% of control values (from 3.28 +/- 1.40 to 0.49 +/- 0.07 ml/kg/min, p < 0.005), prolonged the elimination half-life (from 0.92 +/- 0.32 to 5.1 +/- 0.9 hours, p < 0.001), and caused a twofold increase in peak plasma chlorzoxazone concentrations (20.6 +/- 9.9 versus 38.7 +/- 10.3 micrograms/ml, p < 0.001).",Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513656/),h,0.92,40736,DB00822,Disulfiram
,8513656,elimination half-life,"Disulfiram pretreatment markedly decreased chlorzoxazone elimination clearance to 15% of control values (from 3.28 +/- 1.40 to 0.49 +/- 0.07 ml/kg/min, p < 0.005), prolonged the elimination half-life (from 0.92 +/- 0.32 to 5.1 +/- 0.9 hours, p < 0.001), and caused a twofold increase in peak plasma chlorzoxazone concentrations (20.6 +/- 9.9 versus 38.7 +/- 10.3 micrograms/ml, p < 0.001).",Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513656/),h,5.1,40737,DB00822,Disulfiram
,8513656,peak plasma chlorzoxazone concentrations,"Disulfiram pretreatment markedly decreased chlorzoxazone elimination clearance to 15% of control values (from 3.28 +/- 1.40 to 0.49 +/- 0.07 ml/kg/min, p < 0.005), prolonged the elimination half-life (from 0.92 +/- 0.32 to 5.1 +/- 0.9 hours, p < 0.001), and caused a twofold increase in peak plasma chlorzoxazone concentrations (20.6 +/- 9.9 versus 38.7 +/- 10.3 micrograms/ml, p < 0.001).",Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513656/),[μg] / [ml],20.6,40738,DB00822,Disulfiram
,8513656,peak plasma chlorzoxazone concentrations,"Disulfiram pretreatment markedly decreased chlorzoxazone elimination clearance to 15% of control values (from 3.28 +/- 1.40 to 0.49 +/- 0.07 ml/kg/min, p < 0.005), prolonged the elimination half-life (from 0.92 +/- 0.32 to 5.1 +/- 0.9 hours, p < 0.001), and caused a twofold increase in peak plasma chlorzoxazone concentrations (20.6 +/- 9.9 versus 38.7 +/- 10.3 micrograms/ml, p < 0.001).",Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513656/),[μg] / [ml],38.7,40739,DB00822,Disulfiram
,8513656,formation clearance,"Disulfiram also profoundly decreased the formation clearance of 6-hydroxychlorzoxazone, from 2.30 +/- 0.93 to 0.17 +/- 0.05 ml/kg/min (p < 0.005).",Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513656/),[ml] / [kg·min],2.30,40740,DB00822,Disulfiram
,8513656,formation clearance,"Disulfiram also profoundly decreased the formation clearance of 6-hydroxychlorzoxazone, from 2.30 +/- 0.93 to 0.17 +/- 0.05 ml/kg/min (p < 0.005).",Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513656/),[ml] / [kg·min],0.17,40741,DB00822,Disulfiram
,3005541,clearance,The results showed that the clearance of alcohol was 0.0226 l/min/kg and the elimination rate constant of acetaldehyde from the liver compartment was very large and 35 min-1.,"Effects of diethyldithiocarbamate, a metabolite of disulfiram, on the pharmacokinetics of alcohol and acetaldehyde in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3005541/),[l] / [kg·min],0.0226,41252,DB00822,Disulfiram
,3005541,elimination rate constant,The results showed that the clearance of alcohol was 0.0226 l/min/kg and the elimination rate constant of acetaldehyde from the liver compartment was very large and 35 min-1.,"Effects of diethyldithiocarbamate, a metabolite of disulfiram, on the pharmacokinetics of alcohol and acetaldehyde in the rat. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3005541/),1/[min],35,41253,DB00822,Disulfiram
,1839532,trough drug concentration at steady state (CSSmin),"Dose-corrected, trough drug concentration at steady state (CSSmin) and dose-corrected AUC24h were significantly higher in the patients with liver diseases than in the control subjects [3.4 vs 1.5 ng.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),ng,3.4,46531,DB00822,Disulfiram
,1839532,dose-corrected AUC24h,"Dose-corrected, trough drug concentration at steady state (CSSmin) and dose-corrected AUC24h were significantly higher in the patients with liver diseases than in the control subjects [3.4 vs 1.5 ng.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),ng,1.5,46532,DB00822,Disulfiram
,1839532,elimination t1/2,"The elimination t1/2 was prolonged [83 vs 36 h], but the difference was not statistically significant, and the cirrhotic patients were still able to clear almost all the paroxetine by metabolism.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),h,83,46533,DB00822,Disulfiram
,1839532,elimination t1/2,"The elimination t1/2 was prolonged [83 vs 36 h], but the difference was not statistically significant, and the cirrhotic patients were still able to clear almost all the paroxetine by metabolism.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),h,36,46534,DB00822,Disulfiram
,8513649,peak plasma concentration,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],12 to 22,68577,DB00822,Disulfiram
,8513649,volume of distribution,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[l] / [kg],0.8 to 1.3,68578,DB00822,Disulfiram
,8513649,elimination half-life,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),h,9 to 16,68579,DB00822,Disulfiram
,8513649,clearance,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[ml] / [kg·min],0.7 to 1.5,68580,DB00822,Disulfiram
,8513649,Absolute bioavailability,Absolute bioavailability of oral alprazolam averages 80 to 100%.,Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),%,80 to 100,68581,DB00822,Disulfiram
,8513649,steady-state plasma alpra,"Although a therapeutic concentration range is not clearly established, some studies indicate that optimal reduction of anxiety associated with panic disorder occurs at steady-state plasma alprazolam concentrations of 20 to 40 micrograms/L.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],20 to 40,68582,DB00822,Disulfiram
,27574509,C MAX,Sex differences in PK were evident: females had a higher C MAX (112.4 vs. 68.1 ug/L) and AUC (537.8 vs.,Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],112.4,70205,DB00822,Disulfiram
,27574509,C MAX,Sex differences in PK were evident: females had a higher C MAX (112.4 vs. 68.1 ug/L) and AUC (537.8 vs.,Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],68.1,70206,DB00822,Disulfiram
,27574509,AUC,Sex differences in PK were evident: females had a higher C MAX (112.4 vs. 68.1 ug/L) and AUC (537.8 vs.,Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),,537.8,70207,DB00822,Disulfiram
,27574509,T MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),h,0.25,70208,DB00822,Disulfiram
,27574509,T MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),h,1,70209,DB00822,Disulfiram
,27574509,C MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],109.1,70210,DB00822,Disulfiram
,27574509,C MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],68.1,70211,DB00822,Disulfiram
,27574509,AUC,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[h(∗)ug] / [l],339.7,70212,DB00822,Disulfiram
,27574509,AUC,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[h(∗)ug] / [l],231.8,70213,DB00822,Disulfiram
,2058179,plasma clearance,"2. Across all subjects acetaminophen plasma clearance was reduced from 0.249 +/- 0.061 to 0.217 +/- 0.066 l/min after disulfiram treatment (mean +/- SD, P less than 0.05).",The influence of disulfiram on acetaminophen metabolism in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058179/),[l] / [min],0.249,71004,DB00822,Disulfiram
,2058179,plasma clearance,"2. Across all subjects acetaminophen plasma clearance was reduced from 0.249 +/- 0.061 to 0.217 +/- 0.066 l/min after disulfiram treatment (mean +/- SD, P less than 0.05).",The influence of disulfiram on acetaminophen metabolism in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058179/),[l] / [min],0.217,71005,DB00822,Disulfiram
,2721103,plasma clearance,"With disulfiram pretreatment, the plasma clearance of theophylline was decreased from 105.7 +/- 10.2 (mean +/- SEM) to 83.1 +/- 8.1 ml/kg per hour (p less than 0.001) in the 250 mg group and from 94.3 +/- 13.3 to 65.4 +/- 10.7 ml/mg per hour (p less than 0.001) in the 500 mg group.",Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721103/),[ml] / [h·kg],105.7,86190,DB00822,Disulfiram
,2721103,plasma clearance,"With disulfiram pretreatment, the plasma clearance of theophylline was decreased from 105.7 +/- 10.2 (mean +/- SEM) to 83.1 +/- 8.1 ml/kg per hour (p less than 0.001) in the 250 mg group and from 94.3 +/- 13.3 to 65.4 +/- 10.7 ml/mg per hour (p less than 0.001) in the 500 mg group.",Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721103/),[ml] / [h·kg],83.1,86191,DB00822,Disulfiram
,2721103,plasma clearance,"With disulfiram pretreatment, the plasma clearance of theophylline was decreased from 105.7 +/- 10.2 (mean +/- SEM) to 83.1 +/- 8.1 ml/kg per hour (p less than 0.001) in the 250 mg group and from 94.3 +/- 13.3 to 65.4 +/- 10.7 ml/mg per hour (p less than 0.001) in the 500 mg group.",Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721103/),[ml] / [h·mg],94.3,86192,DB00822,Disulfiram
,2721103,plasma clearance,"With disulfiram pretreatment, the plasma clearance of theophylline was decreased from 105.7 +/- 10.2 (mean +/- SEM) to 83.1 +/- 8.1 ml/kg per hour (p less than 0.001) in the 250 mg group and from 94.3 +/- 13.3 to 65.4 +/- 10.7 ml/mg per hour (p less than 0.001) in the 500 mg group.",Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721103/),[ml] / [h·mg],65.4,86193,DB00822,Disulfiram
,3009000,Peak plasma levels,"Peak plasma levels of 0.3-1.2 mM are observed after a 250-mg/kg dose, with a plasma half-life of 10-20 min.","Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3009000/),mM,0.3-1.2,99814,DB00822,Disulfiram
,3009000,plasma half-life,"Peak plasma levels of 0.3-1.2 mM are observed after a 250-mg/kg dose, with a plasma half-life of 10-20 min.","Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3009000/),min,10-20,99815,DB00822,Disulfiram
,30137649,area under the curve values for 72 hours (AUC0-72 ),"The fitted median area under the curve values for 72 hours (AUC0-72 ) were 3,816, 8,386, and 22,331 mg*hour/L, respectively.",Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30137649/),[h·mg] / [l],"3,816",107426,DB00822,Disulfiram
,30137649,area under the curve values for 72 hours (AUC0-72 ),"The fitted median area under the curve values for 72 hours (AUC0-72 ) were 3,816, 8,386, and 22,331 mg*hour/L, respectively.",Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30137649/),[h·mg] / [l],"8,386",107427,DB00822,Disulfiram
,30137649,area under the curve values for 72 hours (AUC0-72 ),"The fitted median area under the curve values for 72 hours (AUC0-72 ) were 3,816, 8,386, and 22,331 mg*hour/L, respectively.",Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30137649/),[h·mg] / [l],"22,331",107428,DB00822,Disulfiram
,30137649,AUC50,"Higher exposure predicted greater increases in CA-US (maximum effect (Emax ) = 78%, AUC50 = 1,600 μg*hour/L, P = 0.013) but not plasma HIV RNA.",Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30137649/),[h·μg] / [l],"1,600",107429,DB00822,Disulfiram
<,24061865,plasma t½,BEN had a plasma t½ <5 min and produced at least 12 products.,"Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24061865/),min,5,114436,DB00822,Disulfiram
<,24061865,half-lives,The metabolite half-lives were <136 min.,"Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24061865/),min,136,114437,DB00822,Disulfiram
,24061865,AUC0-inf,"Disulfiram increased BEN plasma exposure 368-fold (AUC0-inf from 0.11 to 40.5 mg/L min), while plasma levels of BA remained similar.","Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24061865/),[mg] / [l·min],0.11,114438,DB00822,Disulfiram
,24061865,AUC0-inf,"Disulfiram increased BEN plasma exposure 368-fold (AUC0-inf from 0.11 to 40.5 mg/L min), while plasma levels of BA remained similar.","Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24061865/),[mg] / [l·min],40.5,114439,DB00822,Disulfiram
,971708,half life,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),h,11.0,125321,DB00822,Disulfiram
,971708,half life,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),h,19.0,125322,DB00822,Disulfiram
,971708,metabolic clearance rate,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),[ml] / [min],51.2,125323,DB00822,Disulfiram
,971708,metabolic clearance rate,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),[ml] / [min],33.9,125324,DB00822,Disulfiram
,24013191,flow rate,"Blood samples were pre-stabilized with a stabilizing agent and then plasma was obtained and subjected to solid phase extraction (SPE), and chromatographed on a Phenomenex Kinetex(®) XB C18 column with gradient elution using a mobile phase consisting of acetonitrile-water (containing 0.1% formic acid and 1mM ammonium acetate) at a flow rate of 0.2mL/min for 3min.","A novel UPLC-ESI-MS/MS method for the quantitation of disulfiram, its role in stabilized plasma and its application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013191/),[ml] / [min],0.2,134255,DB00822,Disulfiram
,24013191,extraction recovery,The extraction recovery of disulfiram for different concentrations ranged from 75.7% to 78.3%.,"A novel UPLC-ESI-MS/MS method for the quantitation of disulfiram, its role in stabilized plasma and its application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013191/),%,75.7,134256,DB00822,Disulfiram
,24013191,extraction recovery,The extraction recovery of disulfiram for different concentrations ranged from 75.7% to 78.3%.,"A novel UPLC-ESI-MS/MS method for the quantitation of disulfiram, its role in stabilized plasma and its application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013191/),%,78.3,134257,DB00822,Disulfiram
,21919341,flow rate,"After application of a predictive optimization strategy, the proposed method was developed using a 0.1 M sodium dodecyl sulfate-butanol 4% (v/v) buffered to pH 7 as the mobile phase at a flow rate of 1 mL/min, an octyl silyl (C8) 150 mm column, and diode array detection at 248 nm.",Determination of disulfiram by micellar liquid chromatography in illicit preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21919341/),[ml] / [min],1,177694,DB00822,Disulfiram
below,21919341,analysis time,"Under the above conditions, the analysis time was below 8 min.",Determination of disulfiram by micellar liquid chromatography in illicit preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21919341/),min,8,177695,DB00822,Disulfiram
,21919341,LOD,The LOD (3 x SD criterion) was 15 ng/mL and LOQ (10 x SD criterion) was 70 ng/mL for disulfiram.,Determination of disulfiram by micellar liquid chromatography in illicit preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21919341/),[ng] / [ml],15,177696,DB00822,Disulfiram
,21919341,LOQ,The LOD (3 x SD criterion) was 15 ng/mL and LOQ (10 x SD criterion) was 70 ng/mL for disulfiram.,Determination of disulfiram by micellar liquid chromatography in illicit preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21919341/),[ng] / [ml],70,177697,DB00822,Disulfiram
,21919341,recoveries,"The intraday and interday precisions were below 3.5%, recoveries were in the range of 97-102%, and robustness was below 3%.",Determination of disulfiram by micellar liquid chromatography in illicit preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21919341/),%,97-102,177698,DB00822,Disulfiram
,2551696,plasma half-life,The mean peak plasma concentration of Me-DDC occurred at 1.8 h and its plasma half-life was 6.3 h.,Inhibition of erythrocyte aldehyde dehydrogenase activity and elimination kinetics of diethyldithiocarbamic acid methyl ester and its monothio analogue after administration of single and repeated doses of disulfiram to man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2551696/),h,6.3,205580,DB00822,Disulfiram
,2551696,peak plasma concentration,"In alcoholics with a rapid decrease in erythrocyte ALDH activity (in less than 5 days), the mean peak plasma concentration of Me-DTC was 278 nmol.l-1, whereas the peak concentration was below the detection limit in subjects with a prolonged inactivation time (7-20 days).",Inhibition of erythrocyte aldehyde dehydrogenase activity and elimination kinetics of diethyldithiocarbamic acid methyl ester and its monothio analogue after administration of single and repeated doses of disulfiram to man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2551696/),[nM] / [l],278,205581,DB00822,Disulfiram
,26501354,AUC,"Pharmacokinetic studies showed the markedly improved pharmacokinetic profiles of DSF-S-LNCs (AUC= 3921.391 μg/L·h, t(1/2z) = 1.294 h) compared with free DSF (AUC = 907.724 μg/L·h, t(1/2z) = 0.252 h).",A Copper-Mediated Disulfiram-Loaded pH-Triggered PEG-Shedding TAT Peptide-Modified Lipid Nanocapsules for Use in Tumor Therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501354/),[μg] / [h·l],3921.391,208282,DB00822,Disulfiram
,26501354,t(1/2z),"Pharmacokinetic studies showed the markedly improved pharmacokinetic profiles of DSF-S-LNCs (AUC= 3921.391 μg/L·h, t(1/2z) = 1.294 h) compared with free DSF (AUC = 907.724 μg/L·h, t(1/2z) = 0.252 h).",A Copper-Mediated Disulfiram-Loaded pH-Triggered PEG-Shedding TAT Peptide-Modified Lipid Nanocapsules for Use in Tumor Therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501354/),h,1.294,208283,DB00822,Disulfiram
,26501354,AUC,"Pharmacokinetic studies showed the markedly improved pharmacokinetic profiles of DSF-S-LNCs (AUC= 3921.391 μg/L·h, t(1/2z) = 1.294 h) compared with free DSF (AUC = 907.724 μg/L·h, t(1/2z) = 0.252 h).",A Copper-Mediated Disulfiram-Loaded pH-Triggered PEG-Shedding TAT Peptide-Modified Lipid Nanocapsules for Use in Tumor Therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501354/),[μg] / [h·l],907.724,208284,DB00822,Disulfiram
,26501354,t(1/2z),"Pharmacokinetic studies showed the markedly improved pharmacokinetic profiles of DSF-S-LNCs (AUC= 3921.391 μg/L·h, t(1/2z) = 1.294 h) compared with free DSF (AUC = 907.724 μg/L·h, t(1/2z) = 0.252 h).",A Copper-Mediated Disulfiram-Loaded pH-Triggered PEG-Shedding TAT Peptide-Modified Lipid Nanocapsules for Use in Tumor Therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501354/),h,0.252,208285,DB00822,Disulfiram
,9839087,distribution volume,"At steady-state, acamprosate has a moderate distribution volume of about 20L.",Clinical pharmacokinetics of acamprosate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),l,20,229746,DB00822,Disulfiram
,9839087,terminal,The administration of the enteric-coated tablets showed a flip-flop mechanism with a terminal elimination half-life 10-fold higher than the 3-hour half-life reported after intravenous infusion.,Clinical pharmacokinetics of acamprosate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),h,3,229747,DB00822,Disulfiram
,9839087,accumulation ratio,"The pharmacokinetics of acamprosate administered as an enteric-coated tablets are time- and dose-independent, and its accumulation ratio is about 2.4 at steady-state.",Clinical pharmacokinetics of acamprosate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),,2.4,229748,DB00822,Disulfiram
,29505711,TIRs (tumor inhibition rates,"The TIRs (tumor inhibition rates) of 5-FU, DSF-sol, and DSF-MMs were 63.46, 19.57, and 69.98%, respectively, implying that DSF-MMs slowed the growth of a H22 xenograft tumor model effectively.",mPEG5k- b-PLGA2k/PCL3.4k/MCT Mixed Micelles as Carriers of Disulfiram for Improving Plasma Stability and Antitumor Effect in Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29505711/),%,63.46,230038,DB00822,Disulfiram
,29505711,TIRs (tumor inhibition rates,"The TIRs (tumor inhibition rates) of 5-FU, DSF-sol, and DSF-MMs were 63.46, 19.57, and 69.98%, respectively, implying that DSF-MMs slowed the growth of a H22 xenograft tumor model effectively.",mPEG5k- b-PLGA2k/PCL3.4k/MCT Mixed Micelles as Carriers of Disulfiram for Improving Plasma Stability and Antitumor Effect in Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29505711/),%,19.57,230039,DB00822,Disulfiram
,29505711,TIRs (tumor inhibition rates,"The TIRs (tumor inhibition rates) of 5-FU, DSF-sol, and DSF-MMs were 63.46, 19.57, and 69.98%, respectively, implying that DSF-MMs slowed the growth of a H22 xenograft tumor model effectively.",mPEG5k- b-PLGA2k/PCL3.4k/MCT Mixed Micelles as Carriers of Disulfiram for Improving Plasma Stability and Antitumor Effect in Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29505711/),%,69.98,230040,DB00822,Disulfiram
,359214,elimination half-life (tl/2beta),"The elimination half-life (tl/2beta) of chlordiazepoxide following single doses, in healthy individuals generally ranges from 5 to 30 hours, and the volume of distribution from 0.25 to 0.50 liters/kg.",Clinical pharmacokinetics of chlordiazepoxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/359214/),h,5 to 30,254720,DB00822,Disulfiram
,359214,volume of distribution,"The elimination half-life (tl/2beta) of chlordiazepoxide following single doses, in healthy individuals generally ranges from 5 to 30 hours, and the volume of distribution from 0.25 to 0.50 liters/kg.",Clinical pharmacokinetics of chlordiazepoxide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/359214/),[l] / [kg],0.25 to 0.50,254721,DB00822,Disulfiram
under,359214,hepatic extraction ratio,The hepatic extraction ratio is well under 5%.,Clinical pharmacokinetics of chlordiazepoxide. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/359214/),%,5,254722,DB00822,Disulfiram
less,6941457,binding,The binding to plasma proteins is less than 20%.,Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6941457/),%,20,266243,DB00822,Disulfiram
,6941457,elimination half-lives,"Available data suggest that the elimination half-lives of these drugs differ, being 7-8 h for metronidazole, about 12 h for tinidazole and 14-15 h for ornidazole.",Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6941457/),h,7-8,266244,DB00822,Disulfiram
,6941457,elimination half-lives,"Available data suggest that the elimination half-lives of these drugs differ, being 7-8 h for metronidazole, about 12 h for tinidazole and 14-15 h for ornidazole.",Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6941457/),h,12,266245,DB00822,Disulfiram
,6941457,elimination half-lives,"Available data suggest that the elimination half-lives of these drugs differ, being 7-8 h for metronidazole, about 12 h for tinidazole and 14-15 h for ornidazole.",Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6941457/),h,14-15,266246,DB00822,Disulfiram
,7586950,Michaelis-Menten constants,"In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM).",Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586950/),[mM] / [l],0.14,274074,DB00822,Disulfiram
,7586950,Michaelis-Menten constants,"In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM).",Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586950/),[mM] / [l],0.004,274075,DB00822,Disulfiram
,7586950,maximum velocities,"In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM).",Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586950/),[nM] / [·mg·min],1.3,274076,DB00822,Disulfiram
,7586950,maximum velocities,"In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM).",Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586950/),[nM] / [·mg·min],0.13,274077,DB00822,Disulfiram
